Type Public KK Founded 1 July 1949 | Headquarters Japan Parent organization Kirin Company | |
 | ||
Traded as TYO: 4151
FWB: KY4
Nikkei 225 Component Industry Pharmaceuticals
Biotechnology Key people Nobuo Hanai, (CEO and President) Products Biochemicals
Biosimilars
Diagnostics
Pharmaceuticals Revenue $ 3.548 billion USD (FY 2013)
(¥ 340.61 billion JPY) (FY 2013) Stock price 4151 (TYO) JP¥ 1,726 -24.00 (-1.37%)17 Mar, 3:00 PM GMT+9 - Disclaimer CEO Nobuo Hanai (22 Mar 2012–) Subsidiaries ProStrakan Group plc, Kyowa Kirin plus Co., Ltd. | ||
2014 kyowa hakko kirin co ltd product market pipeline review pharmaceuticals 2014
Kyowa Hakko Kirin Co., Ltd. (協和発酵キリン株式会社, Kyōwa Hakkō Kirin Kabushiki Kaisha) is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index.
Contents
- 2014 kyowa hakko kirin co ltd product market pipeline review pharmaceuticals 2014
- Kyowa hakko kirin co ltd passionate galaxy
- History
- Business segments and products
- References
Kyowa hakko kirin co ltd passionate galaxy
History
On July 1, 1949 the forerunner of the present company, Kyowa Hakko Kogyo Co., Ltd. is established. Following the merger with Kirin Pharma Co., Ltd., on October 1, 2008 the company changed its name to its present.
On July 11, 2014, the KHK subsidiary, ProStrakan Group (based in Scotland), acquired Archimedes Pharma from the Novo Nordisk Foundation for $394 million
Business segments and products
References
Kyowa Hakko Kirin Wikipedia(Text) CC BY-SA